KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52).

Xiaoyong Man, Katya Zaharieva, Grażyna Pulka, Agnieszka Żebrowska, Yunhua Deng, Lally Mekokishvili, Xiaolei Yang, Yunpeng Qi, Cailing Gu, Qingfeng Dong, Min Zheng

J Am Acad Dermatol 93(6) 1448-1455

PMID40784561
PMCID-
DOI10.1016/j.jaad.2025.08.005
发表日期2025-08-10
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: BAT2206 is being developed as a ustekinumab (UST) biosimilar. OBJECTIVES: Equivalent efficacy and comparable safety results of BAT2206 and UST in patients with moderate-to-severe psoriasis up to Week 28 (treatment period [TP] 1) have been reported previously. TP2 (post Week 28 to 52) results are presented here. METHODS: Patients achieving Psoriasis Area and Severity Index response (≥75) at Week 28 entered TP2. Qualified patients of the UST group in TP1 were re-randomized 1:1 into UST-BAT2206 or UST-UST groups, while qualified patients of the BAT2206 group continued with BAT2206 (BAT2206-BAT2206 group). In TP2, secondary efficacy endpoints, pharmacokinetics, safety, and immunogenicity were assessed at Week 32, 40, 44, and 52. RESULTS: A total of 528 patients entered TP2, of which 133, 131, and 264 were assigned to UST-UST, UST-BAT2206, and BAT2206-BAT2206 groups, respectively. The secondary efficacy endpoints and the adverse events showed no obvious differences across all 3 groups. There were no notable differences in the UST serum concentrations. Immunogenicity was comparable, and the switching from UST to BAT2206 did not lead to an increased immunogenicity. LIMITATIONS: No data collected after Week 52. CONCLUSION: Outcomes were comparable among the groups in TP2, with no impact from the UST-to-BAT2206 switch.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。